Our Approach
Our Approach
Our Approach
About Us
Latest news update:
Atorvia awarded inaugural Blue Ticket, sponsored by Merck, at new SpinUp lab at University of Toronto. Read more here.
Pioneering therapies for organ failure
Atorvia is pioneering therapies for organ failure by targeting the regulated cell death pathway that causes it, starting with the kidney.
The first clinical indication we are pursuing is kidney failure caused by cardiac surgery. This form of kidney failure is known as ischemia-induced Acute Kidney Injury (AKI) and is one of the most common causes of complication during cardiac surgery, with anywhere between 30 and 78% of patients developing it depending on the type of surgery. There is nothing surgeons can do to prevent it, and there is no treatment for it.
And this is just the beginning. An estimated 70+ million patients worldwide develop some form of AKI each year, often leaving surviving patients with Chronic Kidney Disease, End Stage Renal Disease, stroke or myocardial infarction. There is still no effective therapy for AKI.
We are on a mission to change that.
Our people
A biotech with a difference, we are on a journey to positively change the lives of patients by ensuring our programs incorporate commercial strategies from the outset. We believe that being unique is powerful, and this applies as much to our people as it does to our strategy, so we are building a company that celebrates diversity and a culture where difference is valued. Although we are small, we are mighty, and we approach our work fearlessly. An inclusive workplace with a global mindset, we welcome people to join us on our journey who will be themselves.
If you’re driven to perform, you’ll fit right in. We are nimble, learn quickly, improve constantly, and celebrate our wins at every turn. Put simply, we hire the best, then let you shine.
We are working quietly in the background on something really special so if you are interested in joining us on our journey, please contact us here.